Search peptides, terms, sources/
Immune and longevity

Elamipretide

Synthetic four-amino-acid peptide studied in rare mitochondrial diseases. US accelerated approval for Barth syndrome; not authorised in the UK. A large phase 3 trial failed.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Preliminary evidence (level 1 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. 1 further finding at this grade showed no effect and is not counted. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Elamipretide is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials4 human trials

What is Elamipretide?

Elamipretide, also called SS-31, is a synthetic four-amino-acid peptide that binds cardiolipin, a lipid found in mitochondria, and is studied in rare mitochondrial diseases. It is not authorised in the UK; the US gave it accelerated approval for Barth syndrome on 19 September 2025, but the 218-person MMPOWER-3 phase 3 trial in primary mitochondrial myopathy did not meet its main endpoints.

Class
Mitochondria-targeted tetrapeptide
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Elamipretide work?

Elamipretide is described in the clinical literature as binding cardiolipin, a lipid in the inner mitochondrial membrane. A 2025 review says it is reported in preclinical and clinical studies to support cardiolipin stability and mitochondrial energy production. This is a proposed mechanism: fitting the biology of a disease does not show that the drug improves how people feel or function.

The mechanism in more detail

Elamipretide is described in the clinical literature as a mitochondrial tetrapeptide that binds cardiolipin, a lipid found in the inner mitochondrial membrane (Thompson et al., Genetics in Medicine 2021). Barth syndrome, the condition it is approved for in the US, is a genetic disorder of cardiolipin metabolism. A 2025 review (Jacob et al., Molecular Genetics and Metabolism) says elamipretide is reported in preclinical and clinical studies to support cardiolipin stability and mitochondrial energy production.

This is a proposed mechanism drawn from trial and review abstracts. A mechanism fitting the biology of a disease does not mean the drug improves how people feel or function: the trial results below are mixed, and one large trial did not meet its main endpoints.

Mechanisms and targets

Cardiolipin binding / mitochondrial support (proposed)Cardiolipin (mitochondrial lipid)

Classification and structure

Names
Elamipretide
Class
Mitochondria-targeted tetrapeptide
Origin
Fully synthetic
Structure
A synthetic tetrapeptide (four amino acids) that binds cardiolipin. Exact sequence and modification detail is not given here.
Routes used in the research
Subcutaneous injection in the cited Barth syndrome and mitochondrial myopathy trials. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Elamipretide has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
30003

1 of the findings graded Preliminary showed no effect, so it is not counted in the evidence grade at the top of the page.

US accelerated approval, Barth syndrome Not graded

On 19 September 2025 the US Food and Drug Administration granted accelerated approval to elamipretide as the first treatment for Barth syndrome in patients weighing at least 30 kg. The approval rests on improved strength of the muscle that straightens the knee, which the FDA calls reasonably likely to predict patient benefit. The FDA requires the manufacturer to run a further randomised, double-blind, placebo-controlled trial to confirm that benefit.

Study type
Regulatory-clinical source
Population
Approval for patients with Barth syndrome weighing at least 30 kg; United States only.
Source
1 FDA, 2025

Limitation: US regulator only; the approval is conditional on a confirmatory trial and rests on a surrogate measure.

Limitations in full

US regulator only; the approval is conditional on a confirmatory trial and rests on a surrogate measure. Press announcement read; prescribing information not read.

Other conditions under study Not graded

A peer-reviewed first-approval summary confirms accelerated US approval in September 2025 for Barth syndrome in adults and children weighing at least 30 kg, and says phase 3 development is described for dry age-related macular degeneration and mitochondrial myopathies.

Study type
Academic publication
Population
Approval and development summary; not a trial.
Source
2 Shirley, 2026

Limitation: Secondary summary.

Limitations in full

Secondary summary. The abstract says 'USA' without naming the agency and gives no exact day. Full text not read.

Barth syndrome crossover trial, primary endpoints not met Preliminary No effect shown

In a 12-person randomised, placebo-controlled crossover trial in Barth syndrome (TAZPOWER), neither primary endpoint was met: the 6-minute walk test and the symptom score did not differ significantly between elamipretide and placebo. In the later open-label part, with no control group, the walk test improved by about 96 metres and the symptom score by 2.1 points in those who reached 36 weeks.

Study type
Human trial
Population
12 people with Barth syndrome randomised; 10 entered the open-label part and 8 reached 36 weeks.
Source
3 Thompson et al., 2021

Limitation: Very small, in an ultra-rare disease.

Limitations in full

Very small, in an ultra-rare disease. The randomised, controlled part was negative on both primary endpoints; the gains are from uncontrolled follow-up and cannot be attributed to the drug with confidence. One author is employed by the developer. Abstract read via Europe PMC; full text not read.

Barth syndrome, 168-week extension Preliminary

In an open-label extension of TAZPOWER, 10 people continued treatment and 8 reached week 168. The walk test improved cumulatively by about 96 metres from extension baseline (p=0.003), and heart volumes improved. There was no control group.

Study type
Human trial
Population
10 people with Barth syndrome; 8 completed 168 weeks.
Source
4 Thompson et al., 2024

Limitation: Open-label, uncontrolled, 10 people, 2 lost by week 168, developer-affiliated authors.

Limitations in full

Open-label, uncontrolled, 10 people, 2 lost by week 168, developer-affiliated authors. Changes in a small uncontrolled group may reflect factors other than the drug. Abstract read via Europe PMC; full text not read.

Phase 3 in mitochondrial myopathy, not met Not graded No effect shown

In MMPOWER-3, a 24-week phase 3 trial of 218 adults with genetically confirmed primary mitochondrial myopathy, elamipretide did not improve either primary endpoint. The 6-minute walk difference versus placebo was -3.2 metres (95% CI -18.7 to 12.3; p=0.69) and the fatigue score difference was -0.07 (p=0.37). The trial failed to show a benefit in this population.

Study type
Human trial
Population
218 adults (109 per arm) with genetically confirmed primary mitochondrial myopathy; mean age 45.6; 74% had mitochondrial DNA changes; double-blind, placebo-controlled, 24 weeks.
Source
5 Karaa et al., 2023

Limitation: Grade describes the reliability of the finding, which is a negative one.

Limitations in full

Grade describes the reliability of the finding, which is a negative one. Population is mitochondrial myopathy, not Barth syndrome, so it does not directly test the approved use. Abstract read via Europe PMC; full text and funder not read.

MMPOWER-3 subgroup analysis Preliminary

A later analysis of MMPOWER-3 found a possible walk-test gain in the subgroup with nuclear DNA variants, no difference from placebo in the larger mitochondrial DNA subgroup, and a trend toward a gain (p=0.06) in people with defects in mitochondrial DNA maintenance genes. The authors used this to design a follow-up phase 3 trial.

Study type
Human trial
Population
Subgroups of adults with primary mitochondrial myopathy from MMPOWER-3.
Source
6 Karaa et al., 2024

Limitation: Post hoc subgroup analysis after a trial that did not meet its primary endpoint.

Limitations in full

Post hoc subgroup analysis after a trial that did not meet its primary endpoint. It generates hypotheses and does not confirm a benefit. The subgroup trend did not reach statistical significance overall.

What safety findings have been reported?

3 safety findings are recorded for Elamipretide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

FDA safety summary

The FDA says the most common side effects of elamipretide were mild-to-moderate injection site reactions, and that serious reactions have also been reported.

Source
1 FDA, 2025

MMPOWER-3 tolerability

In MMPOWER-3, most adverse events were mild to moderate. The abstract gives no event counts.

Source
5 Karaa et al., 2023

Barth syndrome extension

In the 168-week Barth syndrome extension, injection-site reactions were the most common adverse event. Only 10 people took part, too few to rule out rarer harms.

Source
4 Thompson et al., 2024

What is Elamipretide's UK regulatory status?

Marketing authorisation
None identified. Elamipretide does not appear in the MHRA Products database active-substance index (checked 14 November 2026).
Prescription status
Not applicable; there is no licensed UK product to classify.
Medicine class
Not a licensed medicine in the UK. In the US the FDA granted it accelerated approval on 19 September 2025 for Barth syndrome.
MHRA position
No MHRA-authorised product containing elamipretide was found in the Products database on 14 November 2026. Absence from the index is a search result on that date, not a regulatory decision.
Authorised use
None in the UK. In the US only: accelerated approval for Barth syndrome in patients weighing at least 30 kg, based on knee muscle strength, with a confirmatory trial required.
Research use
Studied in clinical trials in Barth syndrome and primary mitochondrial myopathy, and reported in phase 3 development for dry age-related macular degeneration.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework for unlicensed medicinal products.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Elamipretide is recorded as not licensed in the UK (checked 14 November 2026).

References

7 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. US Food and Drug Administration (FDA) (2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. FDA press announcement · Original ↗
  2. Shirley M (2026). Elamipretide: First Approval. DrugsNarrative review · DOI 10.1007/s40265-025-02269-8 · PMID 41335372 · Original ↗
  3. Thompson WR, Hornby B, Manuel R, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in MedicineHuman clinical trial, RCT · DOI 10.1038/s41436-020-01006-8 · PMID 33077895 · Original ↗
  4. Thompson WR, Manuel R, Abbruscato A, et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in MedicineHuman clinical trial · DOI 10.1016/j.gim.2024.101138 · PMID 38602181 · Original ↗
  5. Karaa A, Bertini E, Carelli V, et al. (MMPOWER-3 Trial Investigators) (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. NeurologyHuman clinical trial, RCT · DOI 10.1212/WNL.0000000000207402 · PMID 37268435 · Original ↗
  6. Karaa A, Bertini E, Carelli V, et al. (MMPOWER-3 Trial Investigators) (2024). Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet Journal of Rare DiseasesHuman clinical trial, RCT · DOI 10.1186/s13023-024-03421-5 · PMID 39574155 · Original ↗
  7. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Elamipretide

What is Elamipretide?

Elamipretide, also called SS-31, is a synthetic four-amino-acid peptide that binds cardiolipin, a lipid found in mitochondria, and is studied in rare mitochondrial diseases. It is not authorised in the UK; the US gave it accelerated approval for Barth syndrome on 19 September 2025, but the 218-person MMPOWER-3 phase 3 trial in primary mitochondrial myopathy did not meet its main endpoints. Read what it is.

Is Elamipretide licensed in the UK?

PeptGuru records Elamipretide's UK status as: Not licensed in the UK. None identified. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Elamipretide show?

PeptGuru records 6 research findings for Elamipretide: 4 from human trials and 2 from regulatory or other records. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Elamipretide?

3 safety findings are recorded, including: FDA safety summary; MMPOWER-3 tolerability; barth syndrome extension. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Elamipretide?

All 7 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Elamipretide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • EpithalonEpitalon

    Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.

    Immune and longevityHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK
  • MOTS-cMitochondrial open reading…

    16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.

    Immune and longevityHuman trialsEvidence reviewed
    PreliminaryNot licensed in the UK
  • Thymosin Alpha-1Thymalfasin

    Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.

    Immune and longevityHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Elamipretide with Epithalon

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.